miR-23a与RUNX1在恶性淋巴瘤中的表达及其临床意义
Expression and Clinical Significance of miR-23a and RUNX1 in Malignant Lymphomas
-
摘要:目的 探讨miR-23a与runt相关转录因子(runt-related transcription factor 1, RUNX1)在恶性淋巴瘤中的表达及临床意义。方法 运用荧光素酶报告基因活性分析检测miR-23a与RUNX1基因3′UTR区结合情况。收集150例恶性淋巴瘤及30例反应性增生淋巴组织手术标本, 分别运用原位杂交、免疫组织化学方法检测两组中miR-23a、RUNX1的表达。结果 RUNX1是miR-23a直接调控的靶基因。miR-23a在150例恶性淋巴瘤组织中阳性表达率为66.7%, 显著高于反应性增生淋巴组织(30.0%, P < 0.01), 且与肿瘤恶性程度和临床分期密切相关(P < 0.01);RUNX1蛋白在150例恶性淋巴瘤组织中阳性表达率为24.7%, 显著低于反应性增生淋巴组织(53.3%, P < 0.01), 且与肿瘤组织学类型、恶性程度和临床分期密切相关(P < 0.05);相关性分析表明, miR-23a与RUNX1的表达呈负相关(P < 0.01)。结论 RUNX1是miR-23a直接调控的靶基因, miR-23a的高表达和RUNX1蛋白低表达可能是恶性淋巴瘤发生发展的重要生物学标志。Abstract:Objective To investigate the expression and clinical significance of miR-23a and RUNX1 in malignant lymphomas.Methods Luciferase reporter gene activity was used to evaluate miR-23a targeting of RUNX1.A total of 150 cases with malignant lymphomas and 30 cases with lymphatic tissues with reactive hyperplasia were collected.Hybridization in situ and immunohistochemistry were used to determine the miR-23a and RUNX1 expression in the two groups, respectively.Results MiR-23a was bound to the RUNX1 3'UTR.The positive expression rate of miR-23a was 66.7%in the malignant lymphomas, significantly higher than that in the lymphatic tissues with reactive hyperplasia(30.0%;P < 0.01).This high expression was significanlly correlated with the degree of malignancy and clinical stage(P < 0.01).The positive expression rate of RUNXI was 24.7%in malignant lymphomas, significantly lower than that in the lymphatic tissues with reactive hyperplasia(53.3%;P < 0.01).This low expression was significantly correlated with histological type, degree of malignancy, and clinical stage(P < 0.05).The expression of miR-23a was negatively correlated with that of RUNXI(P < 0.01).Conclusion RUNXI is the target gene of miR-23a.The high expression of miR-23a and lower expression of RUNXI protein may be important biological markers for the onset and progression of malignant lymphoma.
下载: